IADR Abstract Archives
Encapsulated Mesenchymal Stem Cells in Endodontic: A Randomized Clinical Trial
Objectives: The aim of this study was to evaluate the safety and efficacy of encapsulated human umbilical cord mesenchymal stem cells (hUC-MSCs) in a plasma-derived biomaterial for regenerative endodontic procedure (REP) in permanent teeth with apical lesions
Methods: A randomized clinical trial was conducted that included 36 patients with mature incisors, canines or mandibular premolars showing pulp necrosis and radiographic evidence of apical periodontitis. The patients were randomly allocated (1:1) to the REP group or conventional root canal treatment (ENDO group). At the first visit, the access cavity was established and mechanical preparation of the root canal was performed. Calcium hydroxide medication was put into the canal and the cavity was sealed with glass ionomer. Three weeks after the first visit, the ENDO and REP groups each followed a specific protocol. Clinical follow-up examinations were performed at 1 week, 6 months and 1 year. The chi-square test of independence and Fisher’s exact test were used for analysis
Results: At the 1-year follow-up examination, no adverse events were reported and the patients showed 100% clinical success in both groups. In the REP group, laser Doppler flowmetry revealed a significant increase of 22.2 times in unit perfusion (UP) percentage between baseline and 1 year of follow-up (p<0.05). Sensitivity tests revealed an increase in the positive pulp response in the REP group from baseline to 1 year of follow-up
Conclusions: hUC-MSCs encapsulated in a plasma-derived biomaterial are a safe, effective and innovative alternative treatment based on biological principles that promote dentin–pulp regeneration and the health of periapical tissue
Methods: A randomized clinical trial was conducted that included 36 patients with mature incisors, canines or mandibular premolars showing pulp necrosis and radiographic evidence of apical periodontitis. The patients were randomly allocated (1:1) to the REP group or conventional root canal treatment (ENDO group). At the first visit, the access cavity was established and mechanical preparation of the root canal was performed. Calcium hydroxide medication was put into the canal and the cavity was sealed with glass ionomer. Three weeks after the first visit, the ENDO and REP groups each followed a specific protocol. Clinical follow-up examinations were performed at 1 week, 6 months and 1 year. The chi-square test of independence and Fisher’s exact test were used for analysis
Results: At the 1-year follow-up examination, no adverse events were reported and the patients showed 100% clinical success in both groups. In the REP group, laser Doppler flowmetry revealed a significant increase of 22.2 times in unit perfusion (UP) percentage between baseline and 1 year of follow-up (p<0.05). Sensitivity tests revealed an increase in the positive pulp response in the REP group from baseline to 1 year of follow-up
Conclusions: hUC-MSCs encapsulated in a plasma-derived biomaterial are a safe, effective and innovative alternative treatment based on biological principles that promote dentin–pulp regeneration and the health of periapical tissue
3264750_File000004.jpg